About: Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019
Creator	Cohen, Correspondence, Jeffrey
Source	Medline; PMC
abstract	BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is associated with respiratory-related disease and death. Assays to detect virus-specific antibodies are important to understand the prevalence of infection and the course of the immune response. METHODS: Quantitative measurements of plasma or serum antibodies to the nucleocapsid and spike proteins were analyzed using luciferase immunoprecipitation system assays in 100 cross-sectional or longitudinal samples from patients with SARS-CoV-2 infection. A subset of samples was tested both with and without heat inactivation. RESULTS: At >14 days after symptom onset, antibodies against SARS-CoV-2 nucleocapsid protein showed 100% sensitivity and 100% specificity, whereas antibodies to spike protein were detected with 91% sensitivity and 100% specificity. Neither antibody levels nor the rate of seropositivity were significantly reduced by heat inactivation of samples. Analysis of daily samples from 6 patients with COVID-19 showed anti-nucleocapsid and spike protein antibodies appearing between days 8 and 14 after initial symptoms. Immunocompromised patients generally had a delayed antibody response to SARS-CoV-2, compared with immunocompetent patients. CONCLUSIONS: Antibody to the nucleocapsid protein of SARS-CoV-2 is more sensitive than spike protein antibody for detecting early infection. Analyzing heat-inactivated samples with a luciferase immunoprecipitation system assay is a safe and sensitive method for detecting SARS-CoV-2 antibodies.
has issue date	2020-05-19(xsd:dateTime)
bibo:doi	10.1093/infdis/jiaa273
bibo:pmid	32427334
has license	no-cc
sha1sum (hex)	089980d5e7eee347d3cb24494ed6da6215a4c4cf
schema:url	https://doi.org/10.1093/infdis/jiaa273
resource representing a document's title	Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019
has PubMed Central identifier	PMC7313936
has PubMed identifier	32427334
schema:publication	J Infect Dis
resource representing a document's body	covid:089980d5e7eee347d3cb24494ed6da6215a4c4cf#body_text
is schema:about of	named entity 'immune response' named entity 'prevalence' named entity 'infection' named entity 'Bethesda' named entity 'COVID-19' named entity 'antibody' named entity 'risk factor' named entity 'nucleocapsid' named entity 'NIH' named entity 'titer' named entity 'blood donor' named entity 'nucleocapsid' named entity 'blood donors' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'Antibody' named entity 'antibodies' named entity 'Renilla luciferase' named entity 'spike protein' named entity 'antibody' named entity 'antibody' named entity 'IgG' named entity 'Antibodies' named entity 'antibody' named entity 'coronaviruses' named entity 'SARS-CoV-2' named entity 'viral RNA' named entity 'pathogenesis' named entity 'SARS-CoV-2' named entity 'tested positive' named entity 'antibodies' named entity 'NIH' named entity 'nucleocapsid protein' named entity 'antibodies' named entity 'protein' named entity 'RNA' named entity 'nucleocapsid' named entity 'nucleocapsid' named entity 'antibody' named entity 'seropositive' named entity 'SARS-CoV-2' named entity 'plasmid' named entity 'Antibody' named entity 'seronegative' named entity 'antibodies' named entity 'antigen' named entity 'virus' named entity 'polymerase chain reaction' named entity 'SARS-CoV-2' named entity 'infection' named entity 'nucleocapsid' named entity 'nucleocapsid' named entity 'NL63' named entity 'vaccine' named entity 'plasma' named entity 'rank correlation' named entity 'NIH' named entity 'antibodies' named entity 'PCR' named entity 'National Institutes of Health' named entity 'mol/L' named entity 'recombinant' named entity 'confidence intervals' named entity 'Renilla luciferase' named entity 'antibody' named entity 'fever' named entity 'antibodies' named entity 'SARS-CoV-1' named entity 'blood donor' named entity 'antibody' named entity 'viral proteins' named entity 'MERS-CoV' named entity 'North America' named entity 'luciferase' named entity 'antibodies' named entity 'betacoronavirus' named entity 'Fisher exact test' named entity 'infection' named entity 'hematopoietic stem cell transplant' named entity 'synthetic DNA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software